Scholars Central

Research articlePublished 31 May 2022

Endoscopic Transsphenoidal Surgery: Factors Associated with Tumor Progression in Pituitary Adenomas

Authors: Javier Lobato-Polo

Cancer Science & Therapy

Volume 14 · Issue 5 · Pages 1–4

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Objective: The aim of this study was to measure the incidence of tumor recurrence amongst patients that underwent endoscopic transsphenoidal surgery for pituitary adenomas, as well as the performance of the molecular and radiological factors that are commonly associated with recurrence. Methods: Patients of both adult and pediatric population with pituitary adenomas who were treated for the first time with endoscopic transsphenoidal surgery in a single tertiary care center, between June 2006 and December 2019 were included. Clinical features, laboratory results, imaging findings and molecular tests results were collected. Progression was measured in a follow-up MRI. Results: 88 patients were included. 19.5% presented gonadotroph adenomas and non-functional adenomas, followed by corticotrophs (17.2%) and somatotrophs (13.8%). 20.7% had cellular atypia, 26.2% p53 mutation and up to 79.5% had Ki-67 under 3%. On postoperative MRI (available for 90.9% of patients) 43.8% had tumor residue. Tumor progression occurred in 32 patients (36.4%). Median progression-free survival time was 5.37 years (95%CI= 3.29-N/A). Cellular atypia, Ki-67 elevation, cavernous sinus invasion and tumor residue were suggested as significant prognostic factors. Nonetheless, multivariate time-toevent analysis identified tumor residue as the only factor significantly associated with progression: HR=4.0, 95%CI= 1.56 -10.31. Conclusion: Residual tumor in postoperative imaging aids as a predictor for tumor progression and the invasion of the cavernous sinus, presence of cellular atypia and a proliferation index (Ki-67) above 3% influence the speed at which the recurrence appears, therefore not being a predictive factor but rather a modifier of the recurrence.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Javier Lobato-Polo”